643Tip Open-label, Phase II Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Annals of oncology(2021)
摘要
LIV-1 is a transmembrane protein expressed in a variety of cancer types. SGN-LIV1A, or ladiratuzumab vedotin (LV), is a novel, investigational, intravenous, humanized immunoglobulin G1 antibody-drug conjugate (ADC) directed against LIV-1. LV mediates delivery of monomethyl auristatin E, which drives antitumor activity through cytotoxic cell killing and induces immunogenic cell death. In a phase I study, LV (2.5 mg/kg every 21 days) was well tolerated and demonstrated encouraging efficacy in previously treated patients with metastatic breast cancer (Modi 2017).
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要